Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of Pyrazolo[1,5-a]pyrimidine Derivative as a Novel and Selective ALKBH5 Inhibitor for the Treatment of AML
Yingzhe Wang, Hongyu Li, Yan Zhang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 23, pp. 15944-15959
Closed Access | Times Cited: 22

Showing 22 citing articles:

Epigenetics-targeted drugs: current paradigms and future challenges
Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 16
A covalent compound selectively inhibits RNA demethylase ALKBH5 rather than FTO
Gan-qiang Lai, Yali Li, Heping Zhu, et al.
RSC Chemical Biology (2024) Vol. 5, Iss. 4, pp. 335-343
Open Access | Times Cited: 14
Small molecule inhibitors targeting m6A regulators
Guotai Feng, Yongya Wu, Yuan Hu, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 10
Role of m6A modifications in immune evasion and immunotherapy
Chunyu Wu, Lvyuan Li, Qiling Tang, et al.
Medical Oncology (2024) Vol. 41, Iss. 6
Closed Access | Times Cited: 5
RNA m6A modification in ferroptosis: implications for advancing tumor immunotherapy
Jun-Xiao Shi, Zhichao Zhang, Hao-zan Yin, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 5
M6A Demethylase ALKBH5 in Human Diseases: From Structure to Mechanisms
Miaochun Fang, Liwen Ye, Yue Zhu, et al.
Biomolecules (2025) Vol. 15, Iss. 2, pp. 157-157
Open Access
Discovery of maleimide derivatives as m6A demethylase ALKBH5 inhibitors
Luxia Liang, Wenliang Fei, Yingzhe Wang, et al.
Bioorganic & Medicinal Chemistry (2025), pp. 118083-118083
Closed Access
Discovery of a Novel Selective and Cell-Active N6-Methyladenosine RNA Demethylase ALKBH5 Inhibitor
Xianyuan Yang, K. X. Huang, Xu-Nian Wu, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
The role of m6A modification during macrophage metabolic reprogramming in human diseases and animal models
Huiling Wang, Peiqi Xu, Kai Yin, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Development of 3-Arylaminothiophenic-2-carboxylic Acid Derivatives as New FTO Inhibitors Showing Potent Antileukemia Activities
Deyan Zhang, Lu Liu, Ming Li, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117444-117444
Closed Access
Clinical Perspectives in Epitranscriptomics
Eloy Santos-Pujol, Carlos Quero-Dotor, Manel Esteller
Current Opinion in Genetics & Development (2024) Vol. 87, pp. 102209-102209
Open Access | Times Cited: 4
Insights into the m6A demethylases FTO and ALKBH5 : structural, biological function, and inhibitor development
Zewei Gao, Xuan Zha, Min Li, et al.
Cell & Bioscience (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Perspectives on current approaches to virtual screening in drug discovery
Ingo Muegge, Jörg Bentzien, Ge Yunhui
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 10, pp. 1173-1183
Closed Access | Times Cited: 2
Recent advances in noncoding RNA modifications of gastrointestinal cancer
Tomoaki Hara, Sikun Meng, Yasuko Arao, et al.
Cancer Science (2024)
Open Access | Times Cited: 2
Targeting bromodomian-containing protein 8 (BRD8): An advanced tool to interrogate BRD8
Tingting Wu, Yali Chen, Qidong You, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116271-116271
Closed Access | Times Cited: 1
Therapeutic strategies to target the epitranscriptomic machinery
Denise Sighel, Eliana Destefanis, Alessandro Quattrone
Current Opinion in Genetics & Development (2024) Vol. 87, pp. 102230-102230
Open Access | Times Cited: 1
The role of RNA m6A demethylase ALKBH5 in the mechanisms of fibrosis
Ziwei Liao, Jing Wang, Mengrou Xu, et al.
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access | Times Cited: 1
Epitranscriptomic RNA m6A Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities
Mohammad B. Uddin, Zhishan Wang, Chengfeng Yang
Advanced Science (2024)
Open Access | Times Cited: 1
Discovery of the Salicylaldehyde-Based Compound DDO-02267 as a Lysine-Targeting Covalent Inhibitor of ALKBH5
W.D. Fei, Yingzhe Wang, Qi Feng, et al.
European Journal of Medicinal Chemistry (2024), pp. 117183-117183
Closed Access | Times Cited: 1
Current scenario of fused pyrimidines with in vivo anticancer therapeutic potential
Zhi Xu, Li Wang, Hongyan Hu
Archiv der Pharmazie (2024)
Closed Access
mRNA m6A detection
Sharon Moshitch-Moshkovitz, Michal Sevilla-Sharon, Reut Ashwal-Fluss, et al.
Nature Reviews Methods Primers (2024) Vol. 4, Iss. 1
Closed Access
RNA modification in normal hematopoiesis and hematologic malignancies
Xi Chen, Yixiao Yuan, Fan Zhou, et al.
MedComm (2024) Vol. 5, Iss. 11
Open Access
Page 1

Scroll to top